Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
12
×
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
12
×
clinical trials
biotech
new york blog main
new york top stories
san francisco blog main
san diego blog main
san diego top stories
san francisco top stories
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
fda
startups
alnylam pharmaceuticals
bristol-myers squibb
cancer
drugs
glaxosmithkline
intercept pharmaceuticals
new york
nonalcoholic steatohepatitis
sanofi
What
disease
12
×
drug
medicines
approved
new
fda
known
liver
nash
roundup
adds
ago
akcea
bio
cancer
fatty
gene
help
hepatitis
medicine
news
patients
race
research
stop
treatment
year
according
acorda
address
advanced
alliance
allosteric
alnylam
alnylam’s
alzheimer's
american
amyloidosis
approval
areas
Language
unset
Current search:
disease
×
photo
×
" national top stories "
×
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On